Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B

被引:33
作者
van Boemmel, Florian [1 ]
Berg, Thomas [1 ]
机构
[1] Univ Hosp Leipzig, Clin Gastroenterol & Rheumatol, Sect Hepatol, Leipzig, Germany
关键词
HBV; immune control; treatment cessation; withdrawal; TENOFOVIR DISOPROXIL FUMARATE; E-ANTIGEN SEROCONVERSION; CD8(+) T-CELLS; OFF-TREATMENT; CONSOLIDATION THERAPY; VIROLOGICAL RESPONSE; LAMIVUDINE TREATMENT; TREATMENT CESSATION; VIRUS-INFECTION; HBV INFECTION;
D O I
10.1111/liv.13654
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The immune response against the infection is impaired in patients with chronic hepatitis B, and although HBV DNA can effectively be suppressed by nucleos(t)ide analogues (NA), durable immune control is only established in a minority of patients. This especially applies in HBeAg-negative patients who usually must receive lifelong NA treatment. Calculated withdrawal of NA leads to a relapse of HBV DNA in most patients. There is evidence that this sudden exposure of viral antigens can trigger immune control in some patients which may result in HBsAg loss or a form of immune control, then sustained low HBV DNA levels and normal alanine aminotransferase (ALT). In the first prospective randomized trial investigating tenofovir treatment cessation in HBeAg-negative patients, most patients did not need retreatment after NA cessation, although all patients showed a transient relapse in HBV DNA. HBsAg loss was identified in almost 20% nearly 3years after stopping NA. Further confirmation of these findings is needed in larger randomized trials and patients who are most likely to benefit from finite therapy must be identified to individualize NA stopping strategies. However, these results suggest that in patients without risk factors such as cirrhosis or other severe conditions, NA treatment may be stopped, as long as adequate safety rules for retreatment are followed.
引用
收藏
页码:90 / 96
页数:7
相关论文
共 54 条
[1]   Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study [J].
Berg, Thomas ;
Simon, Karl-Georg ;
Mauss, Stefan ;
Schott, Eckart ;
Heyne, Renate ;
Klass, Dietmar M. ;
Eisenbach, Christoph ;
Welzel, Tania Mara ;
Zachoval, Reinhart ;
Felten, Gisela ;
Schulze-zur-Wiesch, Julian ;
Cornberg, Markus ;
Op den Brouw, Marjoleine L. ;
Jump, Belinda ;
Reiser, Hans ;
Gallo, Lothar ;
Warger, Tobias ;
Petersen, Joerg .
JOURNAL OF HEPATOLOGY, 2017, 67 (05) :918-924
[2]   Adaptive immunity in HBV infection [J].
Bertoletti, Antonio ;
Ferrari, Carlo .
JOURNAL OF HEPATOLOGY, 2016, 64 :S71-S83
[3]   Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection [J].
Boni, Carolina ;
Fisicaro, Paola ;
Valdatta, Caterina ;
Amadei, Barbara ;
Di Vincenzo, Paola ;
Giuberti, Tiziana ;
Laccabue, Diletta ;
Zerbini, Alessandro ;
Cavalli, Albertina ;
Missale, Gabriele ;
Bertoletti, Antonio ;
Ferrari, Carlo .
JOURNAL OF VIROLOGY, 2007, 81 (08) :4215-4225
[4]   On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients [J].
Cai, Wei ;
Xie, Qing ;
An, Baoyan ;
Wang, Hui ;
Zhou, Xiaqiu ;
Zhao, Guomin ;
Guo, Qing ;
Gu, Ruiying ;
Bao, Shisan .
JOURNAL OF CLINICAL VIROLOGY, 2010, 48 (01) :22-26
[5]   Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study [J].
Cao, Jiawei ;
Chi, Heng ;
Yu, Tao ;
Li, Zhandong ;
Hansen, Bettina E. ;
Zhang, Xiaoyong ;
Zhong, Chunxiu ;
Sun, Jian ;
Hou, Jinlin ;
Janssen, Harry L. A. ;
Peng, Jie .
JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (04) :581-589
[6]   Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients [J].
Chan, Henry L-Y ;
Wong, Grace L-H ;
Chim, Angel M-L ;
Chan, Hoi-Yun ;
Chu, Shirley H-T ;
Wong, Vincent W-S .
ANTIVIRAL THERAPY, 2011, 16 (08) :1249-1257
[7]   High Frequency of Recurrent Viremia After Hepatitis B e Antigen Seroconversion and Consolidation Therapy [J].
Chaung, Kevin T. ;
Ha, Nghiem B. ;
Trinh, Huy N. ;
Garcia, Ruel T. ;
Nguyen, Huy A. ;
Nguyen, Khanh K. ;
Garcia, Gabriel ;
Ahmed, Aijaz ;
Keeffe, Emmet B. ;
Nguyen, Mindie H. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (10) :865-870
[8]   The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment [J].
Chen, Chien-Hung ;
Lu, Sheng-Nan ;
Hung, Chao-Hung ;
Wang, Jing-Houng ;
Hu, Tsung-Hui ;
Changchien, Chi-Sin ;
Lee, Chuan-Mo .
JOURNAL OF HEPATOLOGY, 2014, 61 (03) :515-522
[9]   Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B [J].
Chi, H. ;
Hansen, B. E. ;
Yim, C. ;
Arends, P. ;
Abu-Amara, M. ;
van der Eijk, A. A. ;
Feld, J. J. ;
de Knegt, R. J. ;
Wong, D. K. H. ;
Janssen, H. L. A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (09) :867-876
[10]   JS']JSH Guidelines for the Management of Hepatitis B Virus Infection [J].
Asahina, Yasuhiro ;
Hayashi, Norio ;
Hiramatsu, Naoki ;
Izumi, Namiki ;
Koike, Kazuhiko ;
Kumada, Hiromitsu ;
Kurosaki, Masayuki ;
Oketani, Makoto ;
Suzuki, Fumitaka ;
Takikawa, Hajime ;
Tanaka, Atsushi ;
Tanaka, Eiji ;
Tanaka, Yasuhito ;
Tsubouchi, Hirohito ;
Yotsuyanagi, Hiroshi .
HEPATOLOGY RESEARCH, 2014, 44 :1-58